Lumonus, a leader in AI powered radiation oncology workflow solutions has raised AUS$25m in a series B funding round.
This funding will help to drive the strong clinical adoption of Lumonus AI, with health systems across the US, Australia, and Europe currently integrating the platform into routine clinical care.
To date, the Lumonus AI platform has supported clinicians in consulting and prescribing over 280,000 cancer treatments and has automated the creation of over 75,000 cancer treatment plans, demonstrating its impact in streamlining critical oncology workflows and improving the efficiency and consistency of care.
The funding round was led by Aviron Investment Management with continued participation from Oncology Ventures.
“Oncology is at an inflection point,” said Keith Hansen, CEO of Lumonus.
“Scientific innovation in cancer treatment has advanced significantly, but the systems that support teams delivering the care have not kept pace.
“By combining AI-native architecture, a comprehensive end-to-end workflow approach, and a commitment to partnering with care teams to solve real-world pain points, we are reimagining oncology workflows. This investment allows us to expand our world-class team and support more health systems that are ready to embrace a better way.”
Chairman Merrick Howes adde: “This milestone reflects the dedication of our entire team, who have worked side by side with clinicians worldwide to demonstrate real impact in oncology today and to show what the future of cancer care can be.
“Our unique AI-native platform has already demonstrated its ability to improve clinical quality and operational efficiency. This new capital will allow us to accelerate both product innovation and expand our US commercial footprint.”
Ben Freeberg, managing partner at Oncology Ventures, said: “The Lumonus team combines deep clinical expertise with world-class product execution and has already earned the trust of leading cancer centers internationally. We are proud to support Lumonus as they continue to deliver measurable impact and set the standard for the future of oncology workflows.”
The funding will be used to expand in the US, advance its flagship products, Lumonus AI Physician and Lumonus AI Dosimetry, and invest in clinical informatics capabilities.
The company will also expand its work with health systems to harness real-world evidence, measure quality, improve operational performance, and deliver more personalised, data-driven care, it said.
Unesco adopts global standards on neurotech 'wild west'
